Advisory Council on Alzheimer's Research, Care, and Services; Meeting, 72377-72378 [2019-28268]

Download as PDF khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 84, No. 250 / Tuesday, December 31, 2019 / Notices into Schedule I of the CSA. As such, additional permanent controls will not be necessary to fulfill United States obligations if 5F–AMB is controlled under Schedule II of the 1971 Convention. 5F-MDMB-PICA (5F-MDMB-2201) (chemical name: methyl 2-(1-(5fluoropentyl)-1H-indazole-3carboxamido)-3,3-dimethylbutanoate) is a synthetic cannabinoid that has been sold online and used to mimic the biological effects of THC, the main psychoactive chemical constituent in cannabis. Research and clinical reports have demonstrated that synthetic cannabinoids are applied onto plant material so that the material may be smoked as users attempt to obtain a euphoric and psychoactive ‘‘high.’’ Synthetic cannabinoids have been marketed under the guise of ‘‘herbal incense,’’ and promoted by drug traffickers as legal alternatives to cannabis. 5F-MDMB-PICA has been associated with law enforcement seizures and overdoses requiring emergency medical intervention. On April 16, 2019, 5F-MDMB-PICA was temporarily controlled as a Schedule I substance under the CSA. As such, additional permanent controls will be necessary to fulfill United States obligations if 5F-MDMB-PICA is controlled under Schedule II of the 1971 Convention. 4F-MDMB-BINACA (4F-ADB) (chemical name: methyl 2-(1-(4fluorobutyl)-1H-indazole-3carboxamido)-3,3-dimethylbutanoate) is a synthetic cannabinoid that is a potent full agonist at CB1 receptors. This substance functionally (biologically) mimics the effects of THC, a Schedule I substance, and the main psychoactive constituent in cannabis. 4F-MDMBBINACA has been encountered in numerous synthetic cannabinoid products that are smoked for their psychoactive effects. Multiple law enforcement encounters of 4F-MDMBBINACA have been reported involving overdose deaths, illicit use, and seizures of drug evidence between December 2018 and February 2019. There are no commercial or approved medical uses for 4F-MDMB-BINACA. 4F-MDMBBINACA is a positional isomer of 5FAMB (chemical name: methyl 2-(1-(5fluoropentyl)-1H-indazole-3carboxamido)-3-methylbutanoate), as defined by 21 CFR 1300.01, and has been a Schedule I controlled substance under the CSA since April 10, 2017. As such, additional permanent controls will not be necessary to fulfill United States obligations if 4F-MDMB-BINACA is controlled under Schedule II of the 1971 Convention. VerDate Sep<11>2014 17:30 Dec 30, 2019 Jkt 250001 4-CMC (4-chloromethcathinone; clefedrone, clephedrone) (chemical name: 1-(4-chlorophenyl)-2(methylamino)propan-1-one) is a synthetic cathinone. 4-CMC produces central nervous system stimulant effects and is abused for its psychoactive properties. 4-CMC abuse has been associated with adverse health effects. 4-CMC has no currently accepted medical use in treatment in the United States. 4-CMC is not controlled under the CSA, but it is considered a Schedule I controlled substance by a number of states in the United States. As such, additional permanent controls will be necessary to fulfill United States obligations if 4-CMC is controlled under Schedule II of the 1971 Convention. N-Ethylhexedrone (chemical name: 2(ethylamino)-1-phenylhexan-1-one; NEH, hexen, Ethyl-Hex) and alpha-PHP (chemical name: 1-phenyl-2-(pyrrolidin1-yl)hexan-1-one; PV-7, apyrrolidinohexanophenone) are synthetic cathinones. N-Ethylhexedrone and alpha-PHP produce central nervous system stimulant effects and are abused for their psychoactive properties. NEthylhexedrone and alpha-PHP have been associated with adverse health effects leading to emergency department admissions, and deaths. NEthylhexedrone and alpha-PHP have no currently accepted medical use in treatment in the United States. On July 18, 2019, N-Ethylhexedrone and alphaPHP were temporarily controlled as a Schedule I substance under the CSA. As such, additional permanent controls will be necessary to fulfill United States obligations if N-Ethylhexedrone and alpha-PHP are controlled under Schedule II of the 1971 Convention. Flualprazolam and etizolam belong to a class of substances known as benzodiazepines. Benzodiazepines produce central nervous system depression and are commonly used to treat insomnia, anxiety, and seizure disorders. Etizolam is currently prescribed in some countries; however, neither drug substance is approved for medical use in the United States. Currently, flualprazolam and etizolam are not controlled under the CSA, but are controlled in a number of states in the United States. As such, additional permanent controls will be necessary to fulfill United States obligations if flualprazolam and etizolam are controlled under Schedule IV of the 1971 Convention. FDA, on behalf of the Secretary of HHS, invites interested persons to submit comments on the notifications from the United Nations concerning these drug substances. FDA, in cooperation with the National Institute PO 00000 Frm 00086 Fmt 4703 Sfmt 4703 72377 on Drug Abuse, will consider the comments on behalf of HHS in evaluating the WHO scheduling recommendations. Then, under section 201(d)(2)(B) of the CSA, HHS will recommend to the Secretary of State what position the United States should take when voting on the recommendations for control of substances under the 1971 Convention at the CND meeting in March 2020. Comments regarding the WHO recommendations for control of crotonyl fentanyl and valeryl fentanyl; under the 1961 Single Convention will also be forwarded to the relevant Agencies for consideration in developing the United States position regarding narcotic substances at the CND meeting. Dated: December 23, 2019. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2019–28269 Filed 12–30–19; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Advisory Council on Alzheimer’s Research, Care, and Services; Meeting Assistant Secretary for Planning and Evaluation, HHS. ACTION: Notice of meeting. AGENCY: This notice announces the public meeting of the Advisory Council on Alzheimer’s Research, Care, and Services (Advisory Council). The Advisory Council provides advice on how to prevent or reduce the burden of Alzheimer’s disease and related dementias on people with the disease and their caregivers. During the January 27, 2020 meeting, an invited panel will present lessons from epidemiology on understanding current rates of dementia, future trends, and potential preventive strategies. The Advisory Council will hear about the Department of Defense’s Peer Reviewed Alzheimer’s Research Program as well as an update on the recommendations from the Alzheimer’s Disease-Related Dementias Research Summit. Federal workgroups will also provide updates on work completed in the last quarter. DATES: The meeting will be held on January 27, 2020 from 9:30 a.m. to 4:15 p.m. EST. ADDRESSES: The meeting will be held in Room 800 in the Hubert H. Humphrey Building, 200 Independence Avenue SW, Washington, DC 20201. Comments: Time is allocated on the agenda to hear public comments. The time for oral comments will be limited SUMMARY: E:\FR\FM\31DEN1.SGM 31DEN1 72378 Federal Register / Vol. 84, No. 250 / Tuesday, December 31, 2019 / Notices to three (3) minutes per individual. In lieu of oral comments, formal written comments may be submitted for the record to Helen Lamont, Ph.D., OASPE, 200 Independence Avenue SW, Room 424E, Washington, DC 20201. Comments may also be sent to napa@ hhs.gov. Those submitting written comments should identify themselves and any relevant organizational affiliations. FOR FURTHER INFORMATION CONTACT: khammond on DSKJM1Z7X2PROD with NOTICES Helen Lamont, 202–260–6075, helen.lamont@hhs.gov. Note: Seating may be limited. Those wishing to attend the meeting must send an email to napa@hhs.gov and put ‘‘January 27 Meeting Attendance’’ in the subject line by Friday, January 17 so that their names may be put on a list of expected attendees and forwarded to the security officers at the Department of Health and Human Services. Any interested member of the public who is a non-U.S. citizen should include this information at the time of registration to ensure that the appropriate security procedure to gain entry to the building is carried out. Although the meeting is open to the public, procedures governing security and the entrance to Federal buildings may change without notice. If you wish to make a public comment, you must note that within your email. SUPPLEMENTARY INFORMATION: Notice of these meetings is given under the Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)(1) and (a)(2)). Topics of the Meeting: During the January 27, 2020 meeting, an invited panel will present lessons from epidemiology on understanding current rates of dementia, future trends, and potential preventive strategies. The Advisory Council will hear about the Department of Defense’s Peer Reviewed Alzheimer’s Research Program as well as an update on the recommendations from the Alzheimer’s Disease Related Dementias Research Summit. Procedure and Agenda: This meeting is open to the public. Please allow 30 minutes to go through security and walk to the meeting room. The meeting will also be webcast at www.hhs.gov/live. Authority: 42 U.S.C. 11225; Section 2(e)(3) of the National Alzheimer’s Project Act. The panel is governed by provisions of Public Law 92–463, as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory committees. Dated: December 19, 2019. Brenda Destro, Deputy Assistant Secretary for Planning and Evaluation, Office of Human Services Policy. [FR Doc. 2019–28268 Filed 12–30–19; 8:45 am] BILLING CODE 4150–05–P VerDate Sep<11>2014 17:30 Dec 30, 2019 Jkt 250001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Dental & Craniofacial Research; Notice of Meeting Disorders Research, National Institutes of Health, HHS) Dated: December 23, 2019. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2019–28244 Filed 12–30–19; 8:45 am] BILLING CODE 4140–01–P Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Dental and Craniofacial Research Council. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Dental and Craniofacial Research Council. Date: January 29, 2020. Open: 8:30 a.m. to 12:00 p.m. Agenda: Report to the Director, NIDCR. Place: National Institutes of Health, Building 45, Conference Room E1/E2, 8600 Rockville Pike, Bethesda, MD 20892. Closed: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Building 45, Conference Room E1/E2, 8600 Rockville Pike, Bethesda, MD 20892. Contact Person: Alicia J. Dombroski, Ph.D., Director, Division of Extramural Activities, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, 301–594–4805, adombroski@nidcr.nih.gov. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: http:// www.nidcr.nih.gov/about, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and PO 00000 Frm 00087 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Topics in Reproductive Biology. Date: January 13, 2020. Time: 1:00 p.m. to 2:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Hui Chen, MD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6164, Bethesda, MD 20892, 301– 435–1044, chenhui@csr.nih.gov. Name of Committee: Risk, Prevention and Health Behavior Integrated Review Group; Psychosocial Risk and Disease Prevention Study Section. Date: January 27–28, 2020. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: The Westgate Hotel, 1055 Second Avenue, San Diego, CA 92101. Contact Person: Stacey FitzSimmons, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3114, MSC 7808, Bethesda, MD 20892, (301) 451– 9956, fitzsimmonss@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Psychosocial Risk and Disease Prevention (PRDP). Date: January 27, 2020. E:\FR\FM\31DEN1.SGM 31DEN1

Agencies

[Federal Register Volume 84, Number 250 (Tuesday, December 31, 2019)]
[Notices]
[Pages 72377-72378]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-28268]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Advisory Council on Alzheimer's Research, Care, and Services; 
Meeting

AGENCY: Assistant Secretary for Planning and Evaluation, HHS.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: This notice announces the public meeting of the Advisory 
Council on Alzheimer's Research, Care, and Services (Advisory Council). 
The Advisory Council provides advice on how to prevent or reduce the 
burden of Alzheimer's disease and related dementias on people with the 
disease and their caregivers. During the January 27, 2020 meeting, an 
invited panel will present lessons from epidemiology on understanding 
current rates of dementia, future trends, and potential preventive 
strategies. The Advisory Council will hear about the Department of 
Defense's Peer Reviewed Alzheimer's Research Program as well as an 
update on the recommendations from the Alzheimer's Disease-Related 
Dementias Research Summit. Federal workgroups will also provide updates 
on work completed in the last quarter.

DATES: The meeting will be held on January 27, 2020 from 9:30 a.m. to 
4:15 p.m. EST.

ADDRESSES: The meeting will be held in Room 800 in the Hubert H. 
Humphrey Building, 200 Independence Avenue SW, Washington, DC 20201.
    Comments: Time is allocated on the agenda to hear public comments. 
The time for oral comments will be limited

[[Page 72378]]

to three (3) minutes per individual. In lieu of oral comments, formal 
written comments may be submitted for the record to Helen Lamont, 
Ph.D., OASPE, 200 Independence Avenue SW, Room 424E, Washington, DC 
20201. Comments may also be sent to [email protected]. Those submitting 
written comments should identify themselves and any relevant 
organizational affiliations.

FOR FURTHER INFORMATION CONTACT: Helen Lamont, 202-260-6075, 
[email protected]. Note: Seating may be limited. Those wishing to 
attend the meeting must send an email to [email protected] and put ``January 
27 Meeting Attendance'' in the subject line by Friday, January 17 so 
that their names may be put on a list of expected attendees and 
forwarded to the security officers at the Department of Health and 
Human Services. Any interested member of the public who is a non-U.S. 
citizen should include this information at the time of registration to 
ensure that the appropriate security procedure to gain entry to the 
building is carried out. Although the meeting is open to the public, 
procedures governing security and the entrance to Federal buildings may 
change without notice. If you wish to make a public comment, you must 
note that within your email.

SUPPLEMENTARY INFORMATION: Notice of these meetings is given under the 
Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)(1) and 
(a)(2)). Topics of the Meeting: During the January 27, 2020 meeting, an 
invited panel will present lessons from epidemiology on understanding 
current rates of dementia, future trends, and potential preventive 
strategies. The Advisory Council will hear about the Department of 
Defense's Peer Reviewed Alzheimer's Research Program as well as an 
update on the recommendations from the Alzheimer's Disease Related 
Dementias Research Summit.
    Procedure and Agenda: This meeting is open to the public. Please 
allow 30 minutes to go through security and walk to the meeting room. 
The meeting will also be webcast at www.hhs.gov/live.

    Authority: 42 U.S.C. 11225; Section 2(e)(3) of the National 
Alzheimer's Project Act. The panel is governed by provisions of 
Public Law 92-463, as amended (5 U.S.C. Appendix 2), which sets 
forth standards for the formation and use of advisory committees.

    Dated: December 19, 2019.
Brenda Destro,
Deputy Assistant Secretary for Planning and Evaluation, Office of Human 
Services Policy.
[FR Doc. 2019-28268 Filed 12-30-19; 8:45 am]
BILLING CODE 4150-05-P